Optimizing Stem Cell Infusion Timing in the Prevention of 1

Acute Graft versus Host Disease

- Yiwen Hou^{1,2,5}, Yue Wu^{1,3,4,5}, Zhonglin Zhang², Liang Wang², Zhiwei Liu², Baolin 3 Tang^{1,3,4}, Kaidi Song^{1,3,4}, Guangyu Sun^{1,3,4}, Xiaoyu Zhu^{1,3,4,*}, Cheng Zhan^{1,2,6,*} 4
- 5 6

2

- ¹Department of Hematology, The First Affiliated Hospital of USTC, Division of Life 7
- Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, 8
- 9 China.
- ²Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Hefei 10

National Research Center for Physical Sciences at the Microscale, Division of Life 11

- Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, 12
- China. 13
- ³Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei, China. 14
- ⁴Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University 15
- 16 of Science and Technology of China, Hefei, China.
- ⁵*These authors contributed equally to this article.* 17
- ⁶Lead contact 18
- **Co-Corresponding authors: Xiaoyu Zhu: xiaoyuz@ustc.edu.cn*; Cheng Zhan: 19
- zhancheng@ustc.edu.cn 20
- 21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 SUMMARY

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone 23 24 treatment for a broad spectrum of malignant and nonmalignant hematological disorders. However, the success of allo-HSCT is often overshadowed by acute graft-versus-host 25 disease (aGVHD), a life-threatening complication with limited preventive options. 26 Here, we found that the incidence and severity of aGVHD after allo-HSCT are highly 27 dependent on the circadian timing of stem cell infusion. The incidence rate of aGVHD 28 in patients decreased by approximately 50% for early infusion (before 2:00 pm) 29 compared to later infusion (after 2:00 pm). Early-infused patients also experienced 30 significantly lower three-year transplant-related mortality and improved GVHD-free, 31 relapse-free survival. Animal studies using an aGVHD mouse model show that this 32 improvement is mainly due to the recipient's rhythm rather than the donor's. 33 Mechanistically, compared with late infusions, early infusions significantly reduced the 34 levels of the pro-inflammatory cytokine IL-1 α following the conditioning regimen and 35 subsequently suppressed T-cell activation and differentiation after transplantation. Our 36 study suggests that scheduling stem cell infusions early in the day could be a simple yet 37 transformative intervention for the prevention of aGVHD. 38

39

40 INTRODUCTION

A primary challenge in allo-HSCT is graft-versus-host disease (GVHD), stemming 41 42 from a potent immunologic assault on the recipient's organs or tissues, which accounts for a considerable proportion of transplant-related mortality post-transplant(Blazar et 43 al., 2012; Ferrara et al., 2009). Current preventative strategies for GVHD include the 44 use of calcineurin inhibitors (CNIs), antimetabolites, and in vivo T cell depletion with 45 anti-thymocyte globulin (ATG)(Bacigalupo et al., 2001; Bolanos-Meade et al., 2023; 46 Ratanatharathorn et al., 1998; Storb et al., 1986; Zeiser and Blazar, 2017). Despite these 47 effective prophylactic measures, 30% to 50% of patients still suffer from acute GVHD 48 (aGVHD) after allogeneic transplantation(Zeiser and Blazar, 2017). Moreover, these 49 interventions can also dampen the beneficial graft-versus-leukemia effect, increasing 50 the risk of infection and disease relapse(Blazar et al., 2012; Shlomchik, 2007). 51 Consequently, there is an ongoing imperative to reduce both the incidence and severity 52 of aGVHD after allo-HSCT. 53

54 The circadian rhythm has emerged as a crucial regulator of immune functions and immune-mediated diseases(Scheiermann et al., 2013). The circadian rhythm can 55 significantly influence various aspects of the hematopoietic system, including the yield, 56 release, migration, and engraftment potential of stem cells(Aardal and Laerum, 1983; 57 Abrahamsen et al., 1998; D'Hondt et al., 2004; Lucas et al., 2008; Mendez-Ferrer et al., 58 2008). However, the implications of circadian rhythms for aGVHD management and 59 patient outcomes in allo-HSCT patients have not been explored. The present protocols 60 for allogeneic transplantation do not typically account for circadian considerations. In 61 this study, we conducted hybrid research involving both allo-HSCT patients and animal 62 models to investigate the impact of the timig of day of stem cell infusion on aGVHD. 63 Our findings underscore that the timing of stem cell infusion profoundly influences the 64 incidence and severity of aGVHD following allo-HSCT. 65

66 **RESULTS**

3

67 The diagram of the clinical research and patient characteristics

From January 2015 to May 2023, 230 consecutive patients who underwent 68 unmanipulated peripheral blood stem cell transplantation (PBSCT) at Anhui Provincial 69 Hospital were screened. All patients received mobilized peripheral blood stem cells as 70 a graft source. For patients who had no matched identical sibling donors or matched 71 unrelated donors, haplo-donors were considered. Patients who received their second 72 73 transplantation were excluded (n = 26). A total of 204 patients who underwent PBSCT using an identical sibling donor (ISD) or haplo-identical donor (HID) were ultimately 74 enrolled in the analysis (Figure S1). 75

76 The patients were categorized based on the stem cell infusion time, which was 77 recorded as the beginning of infusion. The timing of stem cell infusion ranged between 11:00 am and 10:00 pm, and the median time for the whole cohort was 2:00 pm. Patients 78 who received infusions earlier than 2:00 pm were considered the early-infused group 79 (n = 97) with a 1:00 pm median time, and those who received infusions later than or 80 equal to 2:00 pm were considered the late-infused group (n = 107) with a 5:00 pm 81 median time. Table S1 lists the patient demographics and transplantation features, and 82 the baseline characteristics were comparable between the early-infused group (before 83 2:00 pm) and the late-infused group (after 2:00 pm). 84

85 Effect of the infusion timing on GVHD

The cumulative incidence of grade II-IV and III-IV aGVHD by day 100 after allo-86 HSCT was significantly lower (20.6% [95% CI, 13.2-29.2%] vs. 38.3% [95% CI, 29.1-87 47.5%], P = 0.009 for grade II-IV aGVHD; 9.3% [95% CI, 4.5-16.1%] vs. 27.1% [95% 88 CI, 19.0-35.8%], P < 0.001 for grade III-IV aGVHD) in the early-infused group (Figure 89 1). In the early-infused group, 20 patients experienced Grade II-IV aGVHD; among 90 these, 11 met the criteria for Grade II aGVHD (8 of them with gastrointestinal 91 involvement and 4 with cutaneous involvement), the other 9 patients developed Grade 92 III-IV aGVHD (9 with gastrointestinal involvement, 4 with hepatic involvement and 1 93 with cutaneous involvement), and 2 patients died due to uncontrolled aGVHD. In 94

contrast, the late-infused group had 41 patients with Grade II-IV aGVHD, and 12 of 95 those met the criteria for Grade II aGVHD (4 of them with gastrointestinal involvement 96 97 and 8 with cutaneous involvement). A significant portion, 29 patients, progressed to grade III-IV aGVHD (28 with gastrointestinal involvement, 7 with hepatic involvement 98 and 6 with cutaneous involvement), and there were 7 deaths attributable to uncontrolled 99 aGVHD. None of the patients in either circadian infusion group met the criteria for late-100 onset aGVHD. These results clearly demonstrated a markedly lower incidence and 101 102 severity of aGVHD in the early-infused group than in the late-infused group.



Fig. 1 Cumulative incidences of grade II-IV aGVHD (A) and grade III-IV aGVHD (B) in the early-infused group and late-infused group.

To further analyze whether the circadian timing of stem cell infusion is a risk 103 factor for aGVHD, we performed both univariate and multivariate regression analyses 104 considering variables such as age, recipient sex, disease diagnosis (malignant vs. 105 benign), donor/recipient sex compatibility, HLA antibody, ABO compatibility, donor 106 type (ISD vs. HID), conditioning regimen, GVHD prophylaxis regimen, counts of 107 infused total nucleated cells (TNC), counts of infused CD34⁺ cells, usage of MTX, and 108 occurrence of engraftment syndrome (ES) and timing of stem cell infusion. As shown in 109 Table 1, the univariate analysis indicated that the development of Grade II-IV aGVHD 110 was significantly associated with stem cell infusion timing (hazard ratio (HR) = 1.13, 111 95% CI, 1.04-1.23, P = 0.005). All variables with a P value < 0.2 were included in the 112 multivariate regression analysis, which identified stem cell infusion timing (HR = 1.13, 113 95% CI, 1.04-1.23, P = 0.005) as the sole independent risk factor for Grade II-IV 114

115	aGVHD. Moreover, stem cell infusion timing was also a distinct risk factor for the
116	development of Grade III-IV aGVHD according to both univariate and multivariate
117	analyses (HR = 1.16, 95% CI, 1.05-1.27, P = 0.003 in univariate analysis, HR = 1.16,
118	95% CI, 1.05-1.27, $P = 0.003$ in multivariate analysis). Consistent with the findings of
119	previous reports(Flowers et al., 2011; Jagasia et al., 2012), another independent risk
120	factor for Grade III-IV aGVHD was D/R sex compatibility (female to male) (HR = 2.34 ,
121	95% <i>CI</i> , 1.24-4.42, <i>P</i> = 0.01 in univariate analysis, HR = 2.32, 95% <i>CI</i> , 1.24-4.35, <i>P</i> =
122	0.009 in multivariate analysis). These findings underscore the significance of stem cell
123	infusion timing as a pivotal risk factor for aGVHD in PBSCT patients.

Table 1. Univariate and multivariate analyses of the factors associated with acuteGVHD.

	Univariate analysis			Multivariate analysis		
Variable	HR	95%CI	P	HR	95%CI	Р
Grade II-IV acute GVHD						
Age, y	1.01	0.99-1.03	0.210			
Recipient sex						
Female	0.68	0.40-1.14	0.140	0.61	0.36-1.05	0.075
Diagnose						
Malignant	1.45	0.70-3.03	0.320			
D/R sex						
Female to Male	1.35	0.80-2.27	0.260			
HLA antibody						
Positive	0.99	0.51-1.91	0.980			
ABO compatibility	1.13	0.87-1.45	0.370			
Donor type						
ISD	1.21	0.70-2.08	0.50			
~ ** * *						

Conditioning regimen

RIC	0.88	0.48-1.64	0.69			
GVHD Prophylaxis regimen						
without rATG or PT-Cy	1					
with rATG only	0.89	0.37-2.16	0.790			
with PT-Cy only	0.74	0.34-1.61	0.450			
with rATG and PT-Cy	0.90	0.37-2.21	0.820			
Infused TNC count	1.01	0.98-1.03	0.710			
Infused CD34 ⁺ cell count	0.97	0.94-1.01	0.180	0.97	0.93-1.01	0.170
MTX prophylaxis	0.74	0.31-1.73	0.480			
Engraftment syndrome	1.78	0.86-3.69	0.120	1.85	0.87-3.93	0.110
Infusion time	1.13	1.04-1.23	0.005	1.13	1.04-1.23	0.005
Grade III-IV acute GVHD						
Age, y	1.00	0.98-1.02	0.860			
Recipient sex						
Female	0.75	0.39-1.43	0.140	1.14	0.45-2.90	0.780
Diagnose						
Malignant	1.37	0.53-3.55	0.520			
D/R sex						
Female to Male	2.34	1.24-4.42	0.01	2.32	1.24-4.35	0.009
HLA antibody						
Positive	0.81	0.32-2.02	0.650			
ABO compatibility	1.09	0.80-1.50	0.580			
Donor type						
ISD	1.21	0.60-2.43	0.60			

Conditioning regimen

RIC	0.89	0.40-1.96	0.77			
GVHD Prophylaxis regimen						
without rATG or PT-Cy	1					
with rATG only	0.69	0.20-2.30	0.540			
with PT-Cy only	0.70	0.25-1.97	0.500			
with rATG and PT-Cy	1.26	0.43-3.67	0.670			
Infused TNC count	1.01	0.99-1.04	0.250			
Infused CD34 ⁺ cell count	0.96	0.89-1.02	0.170	0.97	0.91-1.03	0.260
MTX prophylaxis	1.05	0.39-2.85	0.920			
Engraftment syndrome	1.85	0.75-4.54	0.180	2.06	0.80-5.31	0.140
Infusion time	1.16	1.05-1.27	0.003	1.16	1.05-1.27	0.003

GVHD, graft-versus-host disease; D/R, donor/recipient; HLA, human leucocyte antigen; ISD,
identical sibling donor; rATG, rabbit anti-thymocyte globulin; PT-Cy, post-transplant
cyclophosphamide; TNCs, total nucleated cells; MTX, methotrexate

The cumulative incidences of 3-year overall and moderate-to-severe chronic GVHD (cGVHD) did not significantly differ between the two groups (P = 0.476 and 0.108, respectively) (**Figure S2**). In the early-infused group, 13 patients developed moderate to severe cGVHD, while 24 patients were affected in the late-infused group. The predominant manifestation among these was sclerodermatous skin changes, present either as an isolated symptom or concomitant with pulmonary, hepatic, or gastrointestinal tract involvement.

136 Effect of circadian rhythm on other transplantation outcomes

While the probabilities of 3-year overall survival (OS) and disease-free survival (DFS) were not significantly different between the two groups (early-infused group vs. lateinfused group: OS, 74.7% [95% *CI*, 64.4-82.5%] vs. 65.5% [95% *CI*, 55.5-73.8%]; DFS, 70.9% [95% *CI*, 60.4-79.1%] vs. 61.6% [95% *CI*, 51.5-70.2%]; P = 0.068, 0.097,respectively), the probability of 3-year GVHD free, relapse-free survival (GRFS) was significantly greater in the early-infused group than in the late-infused group (52.9%

- 143 [95% CI, 42.4-62.4%] vs. 33.9% [95% CI, 25.0-43.0%], P < 0.001) (Figure 2). These
- 144 results suggest that stem cell infusion early in the day could significantly improve long-
- 145 term GRFS after allo-HSCT.



Fig. 2 Transplantation outcomes between the early-infused patients and late-infused patients.

- (A) Probability of overall survival (OS).
- (B) Probability of disease-free survival (DFS).
- (C) Probability of graft-versus-host disease (GVHD) free, relapse-free survival (GRFS).

Among all the patients, 1 had primary graft failure (PGF), and 1 died in the early 146 phase posttransplantation. The cumulative incidence of neutrophil engraftment by day 147 30 was lower in the late-infused group compared to the early-infused group (98.1% [95% 148 CI, 91.3-99.6%] vs. 100.0%, P =0.048) (Figure S3A). One patient in the early-infused 149 group and 5 patients in the late-infused group died before day 100 as a result of 150 transplant-related mortality (TRM) without obtaining platelet recovery. The cumulative 151 incidence of platelet recovery by day 100 was lower in the late-infused group compared 152 to the early-infused group (83.3% [95% CI, 74.5-89.3%] vs. 92.8% [95% CI, 85.1-153 96.6%], P = 0.029) (Figure S3B). In general, early infusions promote the hematopoietic 154 recovery of patients post transplantation. 155

We then compared complications post transplantation between the two groups. Other transplant-related outcomes, such as the incidence of hepatic veno-occlusive disease (HVOD), cytomegalovirus (CMV) antigenemia, hemorrhagic cystitis (HC), bacterial septicemia, and engraftment syndrome (ES), did not significantly differ

160 between the two groups (P > 0.05). As shown in **Table S2**, the stem cell infusion timing 161 did not have a marked impact on other complications after transplantation.

The cumulative incidence of 3-year TRM was significantly lower in the early-162 infused group (13.8% [95% CI, 7.7-21.7%] vs. 24.8% [95% CI, 16.9-33.4%], P =163 0.041), while the incidence of relapse did not significantly differ between the two 164 groups (late-infused group vs. early-infused group, 13.6% [95% CI, 7.8-21.0%] vs. 15.2% 165 [95% CI, 8.7-23.4%] P = 0.843 (Figure 3). Twenty-three patients in the early-infused 166 group and 37 patients in the late-infused group died (Table S3). The primary causes of 167 mortality in the early-infused group were relapse (52.2%), multiorgan dysfunction 168 syndrome (MODS) (17.4%) and infection (13.0%). In the late-infused group, the 169 primary causes were relapse (29.7%), infection (21.6%) and uncontrolled aGVHD 170 (18.9%). Taken together, these results suggest that early infusions of stem cells 171 significantly reduce TRM posttransplantation. 172



Figure 3. Cumulative incidences of 3-year transplant-related mortality (A) and relapse (B) in the early-infused group and late-infused group.

173 Stem cell infusion timing impacts aGVHD in mice

To investigate the underlying mechanisms by which stem cell infusion timing affects aGVHD development and improves prognosis, we utilized an MHC-mismatched allo-HSCT mouse model in which bone marrow cells and splenocytes were transplanted from BALB/c (H2k^d) mice into lethally irradiated C57BL/6J (H2k^b) recipients (i.e., BALB/c→C57BL/6J) at either Zeitgeber Time 5 (i.e., ZT5) or ZT14

179 (Figure 4A). As nocturnal animals, mice are inactive during ZT0 (light onset) to ZT12

and active from ZT12 (dark onset) to ZT24. Thus, ZT14 corresponds to early in the day

181 in humans, while ZT5 corresponds late in the day.

Interestingly, mice transplanted at ZT14 (ZT14 group) exhibited a significantly 182 lower mortality rate (Figure 4B) and less severe weight loss (Figure 4C) than those 183 transplanted at ZT5 (ZT5 group). Crucially, the ZT14 group also had significantly 184 185 lower aGVHD scores (Figure 4D, E) and significantly lower cumulative incidences of aGVHD of 2-6, 3-6, and 4-6 scores (Figure 4F). Histopathologic analyses further 186 corroborated these findings, revealing decreased tissue injury and inflammation in the 187 skin, lungs, colon, and liver in the ZT14 group compared to the ZT5 group (Figure 4G, 188 H). No significant differences were observed between the groups regarding donor 189 chimerism rates (Figure S4). Collectively, these findings indicate a lower incidence 190 and severity of aGVHD in the ZT14 group relative to the ZT5 group. 191

192 The Recipient's Circadian Rhythm is Crucial

193 To ascertain whether aGVHD incidence is affected more by the circadian rhythmicity of the recipient or donor, we administered stem cells from donors at ZT5 or ZT14 to 194 ZT5 and ZT14 recipients post-irradiation (Figure 4I). Significant differences were 195 observed in survival rates and aGVHD scores based on the recipients' circadian rhythm, 196 with ZT14 recipients demonstrating substantially lower aGVHD scores than their ZT5 197 counterparts, regardless of the donor's circadian rhythm (Figure 4J-L). Even when 198 donor rhythmicity was altered to ZT1 and ZT9, ZT14 recipients consistently exhibited 199 less severe aGVHD symptoms compared to ZT5 recipients (Figure S5). Conversely, 200 modifications to only the donor's circadian rhythm did not significantly alter survival 201 rates, bodyweight, or aGVHD scores (Figure 4J-L). Therefore, these results suggest 202 that the influence of the infusion timing on aGVHD is mainly due to the recipient's 203 rhythm rather than the donor's. 204



Fig. 4 The impacts of stem cell infusion timing on aGVHD in mice.

(A) Schematic of allo-HSCT in mice. C57BL/6J recipient mice at ZT5 and ZT14 received bone marrow cells and splenocytes (SPL) transplantation from BALB/c donor mice by tail vein injection following lethal total-body irradiation.

(B-D) Survival rate **(B)**, body weight **(C)**, and aGVHD score **(D)** of lethally irradiated recipients after allo-HSCT. Data shown derive from three independent experiments.

(E) Representative examples showing phenotypic differences on day 45 after allo-HSCT from the ZT5 (top) and ZT14 (bottom) groups.

(F) Cumulative incidences of aGVHD scores at 2-6 (left), 3-6 (middle) and 4-6 (right) in the ZT5 and ZT14 groups.

(G and H) Histopathologic analysis of skin, liver, lung, and colon section on day 45 after allo-HSCT. Representative images of hematoxylin and eosin staining (G) and quantification results (n=5-7 independent mice per group combined from three replicate experiments) (H). Scale bars, 200 μ m.

(I-L) The effects of recipient's and donor's rhythms on aGVHD. I, Experimental schematic. Both ZT5 and ZT14 recipient mice received transplantation from ZT5 or ZT14 donor mice.

Survival rate (J), body weight (K), and aGVHD score (L).

Data are presented as means \pm SEMs and analyzed by two-way ANOVA followed by Bonferroni post hoc test (**C**, **D**, **K** and **L**), unpaired *t* test (**H**) and log-rank test (**B** and **J**).

205 Cytokine levels and T-cell activation

The pathophysiology of aGVHD consists of three phases(Ferrara et al., 2009; 206 Schroeder and DiPersio, 2011): (1) initial production of danger signals, such as pro-207 inflammatory cytokines, due to the conditioning regimen; (2) donor T cell activation 208 209 and cytokine release; and (3) resultant host tissue damage. Given the significant effect of stem cell infusion timing on aGVHD outcomes, we hypothesized that these effects 210 predominantly occur during the early stages of aGVHD development. We began by 211 examining cytokine levels in murine serum following irradiation. Of the thirteen 212 cytokines assessed, only IL-1a was significantly lower in the ZT14 recipients than in 213 the ZT5 recipients (Figure 5A), and no significant differences were observed for the 214 other cytokines. IL-1a is a classic damage-associated molecular pattern (DAMP) 215 molecule produced in response to cell death and tissue damage(Malik and Kanneganti, 216 217 2018). These results suggest less pronounced tissue damage from irradiation in the ZT14 group. 218

IL-1α plays critical roles in inducing T cell activation(Ferrara et al., 1993). We 219 then examined whether donor T cell activation was affected by the timing of stem cell 220 infusion, using the activation marker CD38 (Figure S6). At 24 hours (day 1) after allo-221 HSCT, both the percentages and absolute numbers of donor activated (H2k^{d+} CD38⁺) 222 $CD4^+$ T cells were significantly lower in the ZT14 group than in the ZT5 group (Figure 223 5B). Although there was no significant difference in the percentage of donor activated 224 $(H2k^{d+} CD38^{+}) CD8^{+} T$ cells between the two groups, the absolute number of donor 225 activated CD8⁺T cells was substantially lower in the ZT14 group than in the ZT5 group 226 (Figure 5C). IFNy, released by activated T cells post-transplant, usually signals 227 heightened T cell activation(Schroeder and DiPersio, 2011). In line with this, post-228 transplant IFNy levels were significantly lower in the ZT14 group than in the ZT5 group 229

- 230 (Figure 5D). These findings indicate substantially decreased T cell activation in the
- 231 ZT14 group compared with the ZT5 group after transplantation.



Fig. 5 The impacts of the stem cell infusion timing on cytokine levels and T cell activation.

(A) Absolute (top) and normalized (bottom) cytokine levels in the sera of recipient mice 5 hours after lethal irradiation. Mice were exposed to lethal irradiation at ZT0 and ZT9, with serum samples collected at ZT5 and ZT14 on the same day. For the bottom panel, cytokine levels in the ZT14 group were normalized to those in the ZT5 group for each cytokine.

(**B** and **C**) Representative dot plots (left), proportions (right top) and absolute counts (right bottom) of donor activated (H2 k^{d+} CD3 8^+) CD4⁺ T cells (**B**) and CD8⁺ T cells (**C**) in the spleen of recipient mice 24 hours (day 1) after allo-HSCT.

(**D**) Absolute (top) and normalized (bottom) cytokine levels in the sera of recipient mice 24 hours after allo-HSCT. Stem-cell infusions were performed allo-HSCT at ZT5 and ZT14, and serum samples were collected 24 hours later. For the bottom panel, cytokine levels in the ZT14 group were normalized to those in the ZT5 group for each cytokine.

Data are presented as means \pm SEMs and analyzed by unpaired *t* test. TBI, total body irradiation. ns, not significant.

We further identified the differentiation state of the donor T cells by examining 232 CD44 and CD62L expression. On day 1 after allo-HSCT, the percentage of naïve 233 (CD44⁻ CD62L⁺) T cells was significantly greater in the ZT14 group than in the ZT5 234 group (Figure 6A, C). In contrast, the percentages of donor central memory (CD44⁺ 235 $CD62L^+$) and effector memory ($CD44^+$ $CD62L^-$) T cells (including both the $CD4^+$ and 236 CD8⁺ subsets) were significantly lower in the ZT14 group than in the ZT5 group 237 (Figure 6A, C). LikewiseSimilarly, the percentage of donor effector memory T cells 238 was significantly lower in the ZT14 group than in the ZT5 group 7 days after allo-239 HSCT (Figure 6B, D). Effector memory T cells can quickly produce cytokines and 240 mediate immune responses against host tissue, which contributes to the pathology of 241 aGVHD. Thus, these results suggest that early infusion (ZT14) may decrease the 242 proportion of effector memory T cells, potentially creating an immune environment less 243 conducive to the development of the harmful immune responses associated with 244 aGVHD. 245





(**A** and **B**) Representative dot plots (left) and proportions (right) of CD4⁺ T_{naive} , T_{CM} , and T_{EM} cells in the spleen of recipient mice on day one (**A**) and day seven (**B**) after allo-HSCT. (**C** and **D**) Representative dot plots (left) and proportions (right) of CD8⁺ $T_{naïve}$, T_{CM} , and T_{EM} cells in the spleen of recipient mice on day one (**C**) and day seven (**D**) after allo-HSCT. Data are presented as means \pm SEMs and analyzed by unpaired t test.

246 **DISCUSSION**

In this study, through retrospective analysis of clinical data, we found that altering the 247 248 timing of stem cell infusion can unexpectedly impact the incidence and severity of aGVHD in patients receiving ISD or HID-HSCT. Notably, patients received stem cell 249 infusions before 2:00 pm had significantly less incidence and severity of aGVHD, lower 250 TRM and better survival than did those treated after 2:00 pm. Currently, in medical 251 practice, timing decisions for stem cell infusions typically hinge on staff convenience. 252 Our results suggest that, pending validation through prospective multicenter studies that 253 include varied graft types, prioritizing infusions before early afternoon could improve 254 outcomes in allo-HSCT procedures. Making such scheduling arrangements holds 255 promise for substantially improving patient prognosis and quality of life. 256

Our animal study corroborated that stem cell infusions administered early (ZT14) 257 in the day significantly attenuate the risk of aGVHD following allo-HSCT compared to 258 those administered late (ZT5) in the day. A key finding is that the recipient's circadian 259 260 rhythm plays a critical role in this dynamic. Mechanistically, compared with those in the late-infused group, the mice in the early-infused group exhibited significantly lower 261 levels of the pro-inflammatory cytokine IL-1a following the conditioning regimen and 262 subsequent reductions in T-cell activation and differentiation after transplantation. 263 Furthermore, we observed significantly lower percentages of effector memory T cells 264 in the ZT14 group than in the ZT5 group. These insights align with the current 265 understanding that the incidence and severity of aGVHD are intricately associated with 266 the levels of pro-inflammatory cytokines and T cell status(Blazar et al., 2012; Cooney 267 et al., 1991; Welniak et al., 2000). The immune system is highly regulated by the 268 circadian rhythm(Wang et al., 2022). In the future, exploring the mechanisms by which 269 circadian timing influences the production of pro-inflammatory cytokines and T cell 270 activation and differentiation in the context of allo-HSCT will be of substantial interest. 271

272

The often-neglected influence of circadian rhythms is emerging as a pivotal factor

in clinical practice(Klerman et al., 2022; Levi et al., 1997; McKenna et al., 2018). For 273 instance, a recent study of melanoma immunotherapy indicated that administering 274 immune checkpoint inhibitors prior to 4:30 pm markedly improved treatment outcomes 275 compared to later infusions(Qian et al., 2021). Our research bolsters the idea that 276 administering the appropriate intervention at the optimal time can improve patient 277 prognosis. To the best of our knowledge, this study is the first to identify the circadian 278 timing of stem cell infusion as an independent risk factor for aGVHD development. 279 280 Given the significant and far-reaching impact on aGVHD and long-term survival achieved by simply altering the timing of stem cell infusion, we believe that the timing 281 of stem cell infusion itself may represent a critical window for clinical intervention. 282 Our findings also highlight the importance of considering circadian factors when 283 evaluating the effectiveness of drugs and treatments for aGVHD. Given that aGVHD 284 following allo-HSCT is inherently a transplant-related immune rejection condition-a 285 phenomenon prevalent in diverse organ transplant scenarios-it is of great interest to 286 investigate how circadian rhythms may affect immune rejection in other types of organ 287 288 transplantations.

289

ACKNOWLEDGMENTS

We thank Dr. Haiming Wei's laboratory at the USTC for assisting in the development 290 of the aGVHD mouse model. We thank the animal facility and flow cytometry facility 291 at USTC for their technical support. We appreciate the insightful suggestions and 292 comments provided by the Neuroscience Pioneer Club to improve this manuscript. 293 Cheng Zhan is supported by grants from the Research Funds of Center for Advanced 294 295 Interdisciplinary Science and Biomedicine of IHM (QYPY20220018), the National Natural Science Foundation of China (32271063, 31822026, 31500860), and the 296 National Science and Technology Innovation 2030 Major Project of China 297 (2021ZD0203900). Xiaoyu Zhu is supported by grants from the National Natural 298 Science Foundation of China (82270223), the Anhui Provincial Department of 299 Education Scientific Research Project (2023AH010079) and the Anhui Provincial 300

301 Natural Science Foundation (2308085J09).

302 AUTHOR CONTRIBUTIONS

303 Cheng Zhan and Xiaoyu Zhu conceived the study and wrote the manuscript. Yue Wu,

304 Baolin Tang, Kaidi Song, and Guangyu Sun contributed to the clinical data collection

and data analysis. Yiwen Hou, Zhonglin Zhang and Zhiwei Liu developed the aGVHD

306 mouse model and evaluated the pathological score. Yiwen Hou and Liang Wang

307 performed the flow cytometry experiments. The data analysis presented in this study

308 was carried out by Yue Wu and Yiwen Hou. Yue Wu and Yiwen Hou contributed equally

309 to this manuscript.

310 **DECLARATION OF INTERESTS**

311 The authors declare no competing interests.

312 **REFERENCES**

Aardal, N.P., and Laerum, O.D. (1983). Circadian variations in mouse bone marrow. Exp Hematol *11*, 792-801.

Abrahamsen, J.F., Smaaland, R., Sothern, R.B., and Laerum, O.D. (1998). Variation in cell yield and

proliferative activity of positive selected human CD34+ bone marrow cells along the circadian time
scale. Eur J Haematol *60*, 7-15.

- Bacigalupo, A., Lamparelli, T., Bruzzi, P., Guidi, S., Alessandrino, P.E., di Bartolomeo, P., Oneto, R.,
 Bruno, B., Barbanti, M., Sacchi, N., *et al.* (2001). Antithymocyte globulin for graft-versus-host
 disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo
 Italiano Trapianti Midollo Osseo (GITMO). Blood *98*, 2942-2947.
- Blazar, B.R., Murphy, W.J., and Abedi, M. (2012). Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol *12*, 443-458.
- Bolanos-Meade, J., Hamadani, M., Wu, J., Al Malki, M.M., Martens, M.J., Runaas, L., Elmariah, H.,
- Rezvani, A.R., Gooptu, M., Larkin, K.T., *et al.* (2023). Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med *388*, 2338-2348.
- 327 Cooney, R., Owens, E., Jurasinski, C., Gray, K., Vannice, J., and Vary, T. (1991). Interleukin-1 receptor
- 328 antagonist prevents sepsis-induced inhibition of protein synthesis. Am J Physiol *267*, E636-641.
- 329 D'Hondt, L., McAuliffe, C., Damon, J., Reilly, J., Carlson, J., Dooner, M., Colvin, G., Lambert, J.F., Hsieh,
- 330 C.C., Habibian, H., *et al.* (2004). Circadian variations of bone marrow engraftability. J Cell Physiol
- 331 *200*, 63-70.
- 332 Ferrara, J.L., Abhyankar, S., and Gilliland, D.G. (1993). Cytokine storm of graft-versus-host disease:
- a critical effector role for interleukin-1. Transplant Proc 25, 1216-1217.
- Ferrara, J.L., Levine, J.E., Reddy, P., and Holler, E. (2009). Graft-versus-host disease. Lancet 373,

335 1550-1561.

- 336 Flowers, M.E., Inamoto, Y., Carpenter, P.A., Lee, S.J., Kiem, H.P., Petersdorf, E.W., Pereira, S.E., Nash,
- 337 R.A., Mielcarek, M., Fero, M.L., et al. (2011). Comparative analysis of risk factors for acute graft-
- versus-host disease and for chronic graft-versus-host disease according to National Institutes of
 Health consensus criteria. Blood *117*, 3214-3219.
- 340 Jagasia, M., Arora, M., Flowers, M.E., Chao, N.J., McCarthy, P.L., Cutler, C.S., Urbano-Ispizua, A.,
- Pavletic, S.Z., Haagenson, M.D., Zhang, M.J., *et al.* (2012). Risk factors for acute GVHD and survival
 after hematopoietic cell transplantation. Blood *119*, 296-307.
- 343 Klerman, E.B., Brager, A., Carskadon, M.A., Depner, C.M., Foster, R., Goel, N., Harrington, M.,
- Holloway, P.M., Knauert, M.P., LeBourgeois, M.K., *et al.* (2022). Keeping an eye on circadian time
 in clinical research and medicine. Clin Transl Med *12*, e1131.
- Levi, F., Zidani, R., and Misset, J.L. (1997). Randomised multicentre trial of chronotherapy with
 oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization
 for Cancer Chronotherapy. Lancet *350*, 681-686.
- Lucas, D., Battista, M., Shi, P.A., Isola, L., and Frenette, P.S. (2008). Mobilized hematopoietic stem
 cell yield depends on species-specific circadian timing. Cell Stem Cell *3*, 364-366.
- Malik, A., and Kanneganti, T.D. (2018). Function and regulation of IL-1alpha in inflammatory
 diseases and cancer. Immunol Rev *281*, 124-137.
- McKenna, H., van der Horst, G.T.J., Reiss, I., and Martin, D. (2018). Clinical chronobiology: a timely
 consideration in critical care medicine. Crit Care *22*, 124.
- Mendez-Ferrer, S., Lucas, D., Battista, M., and Frenette, P.S. (2008). Haematopoietic stem cell
 release is regulated by circadian oscillations. Nature *452*, 442-447.
- 357 Qian, D.C., Kleber, T., Brammer, B., Xu, K.M., Switchenko, J.M., Janopaul-Naylor, J.R., Zhong, J.,
- 358 Yushak, M.L., Harvey, R.D., Paulos, C.M., et al. (2021). Effect of immunotherapy time-of-day
- 359 infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a
- propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol 22, 17771786.
- 362 Ratanatharathorn, V., Nash, R.A., Przepiorka, D., Devine, S.M., Klein, J.L., Weisdorf, D., Fay, J.W.,
- Nademanee, A., Antin, J.H., Christiansen, N.P., *et al.* (1998). Phase III study comparing methotrexate
 and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease
- prophylaxis after HLA-identical sibling bone marrow transplantation. Blood *92*, 2303-2314.
- Scheiermann, C., Kunisaki, Y., and Frenette, P.S. (2013). Circadian control of the immune system.
 Nat Rev Immunol *13*, 190-198.
- 368 Schroeder, M.A., and DiPersio, J.F. (2011). Mouse models of graft-versus-host disease: advances 369 and limitations. Dis Model Mech *4*, 318-333.
- 370 Shlomchik, W.D. (2007). Graft-versus-host disease. Nat Rev Immunol 7, 340-352.
- 371 Storb, R., Deeg, H.J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C.D., Clift, R.,
- 372 Doney, K., Farewell, V., et al. (1986). Methotrexate and cyclosporine compared with cyclosporine
- alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
- 374 N Engl J Med *314*, 729-735.
- Wang, C., Lutes, L.K., Barnoud, C., and Scheiermann, C. (2022). The circadian immune system. Sci
 Immunol *7*, eabm2465.
- 377 Welniak, L.A., Blazar, B.R., Anver, M.R., Wiltrout, R.H., and Murphy, W.J. (2000). Opposing roles of
- 378 interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning.

Biol Blood Marrow Transplant *6*, 604-612.

- Zeiser, R., and Blazar, B.R. (2017). Acute Graft-versus-Host Disease Biologic Process, Prevention,
- 381 and Therapy. N Engl J Med *377*, 2167-2179.

382

Supplementary Figures and Tables



Figure S1. Diagram of patients enrolled in this study. Allo-PBSCT allogeneic peripheral blood stem cell transplantation.





Figure S2. Cumulative incidences of overall cGVHD (A) and moderate to severe cGVHD (B) in the early infused group and late infused group.



Figure S3. Cumulative incidences of neutrophil engraftment by day 42 (A) and platelet recovery by day 100 (B) in the early infused group and late infused group.



Figure S4. Impact of stem cell infusion timing on donor chimerism.

(A) H-2K^b and H-2K^d staining of peripheral blood in untransplanted C57BL/6J mice (left), BALB/c mice (middle), and transplanted C57BL/6J mice (right) on day14 following allo-HSCT.

(B) Donor chimerism in peripheral blood of ZT5 and ZT14 groups on day 14 after allo-HSCT (ZT5 n=5, ZT14 n=4).

Data are presented as means \pm SEM and analyzed using unpaired *t* test.





Figure S5. Impacts of the rhythms of recipient and donor mice on aGVHD development. (A) Experimental schematic. Both ZT5 and ZT14 recipient mice received BM cells and splenocytes transplantation from ZT1 or ZT9 donor mice.

(B-D) Survival rate (B), body weight (C) and aGVHD score (D) of recipient mice.

Data are presented as means ± SEM and analyzed by two-way ANOVA followed by Bonferroni post hoc test (C and D) and log-rank test (B).





Figure S6. Gating strategy in flow cytometry analysis.

Starting from upper left panel and going down following the arrows in dotted lines, we gated successively: lymphocytes, CD45⁺ live cells, H2kd⁺ donor cells, and T (CD3⁺) cells. Donor T cells were subdivided into CD4⁺ T and CD8⁺ T-cell subsets. Naïve T cells (CD44⁻CD62L⁺, $T_{naïve}$), central memory T cells (CD44⁺CD62L⁺, T_{CM}), and effector memory T cells (CD44⁺CD62L⁻, T_{EM}) were gated according to the expression of CD44 and CD62L.CounteBeads were added to cell suspensions for absolute cell counting.

early infused group late infused group Characteristics Р (n=97) (n=107) 0.780 Sex, n (%) Male 53 (54.6) 56 (52.3) Female 44 (45.4) 51 (47.7) 32 (4-61) 32 (3-62) 0.279 Age (years), Median (Range) Weight(kg), Median (Range) 0.967 60 (14-92) 62 (14-109) Diagnostics, n (%) 0.385 AML 42 (43.3) 36 (33.6) ALL 19 (19.6) 17 (15.9) MDS/MPN 19 (19.6) 32 (29.9) AA 15 (15.5) 20 (18.7) Others* 2 (2.1) 2 (1.9) Donor type, n (%) 1.000 ISD 65 (67.0) 72 (67.3) HID 32 (33.0) 35 (32.7) $CD34^+$ cell infused (10⁶/kg) 5.62 (0.32-67.5) 4.90 (0.66-36.30) 0.375 TNCs infused $(10^8/\text{kg})$ 9.95 (2.50-101.32) 9.59 (2.35-56.95) 0.284 0.333 Female to male, n (%) Yes 21 (21.6) 30 (28.0) No 76 (78.4) 77 (72.0) Conditioning regimen, n (%) 1.000 MAC 74 (76.3) 82 (76.6)

Table S1. Characteristics of patients between the early infused group and late infused group.

RIC	23 (23.7)	25 (23.4)	
MTX prophylaxis, n (%)	8 (8.2)	12 (11.2)	0.638
Prophylaxis drug, n (%)			0.991
Without rATG or PT-Cy	65 (67.0)	72 (67.3)	
With rATG only	10 (10.3)	12 (11.2)	
With PT-Cy only	14 (14.4)	14 (13.1)	
With both rATG and PT-Cy	8 (8.2)	9 (8.4)	
ABO incompatibility, n (%)			0.844
Identical	51 (52.6)	60 (56.1)	
Minor incompatibility	19 (19.6)	24 (22.4)	
Major incompatibility	16 (16.5)	18 (16.8)	
Bidirectional incompatibility	11 (11.3)	5 (4.7)	
Follow-up time among survivors (month)	50.3 (7.1-106.1)	42.2 (7.5-101.9)	0.284

ISD identical sibling donor, HID haplo-identical donor, TNCs total nucleated cells, MAC myeloablative conditioning regimen, RIC reduced intensity conditioning, MTX methotrexate, rATG rabbit anti-thymocyte globulin, PT-Cy post-transplant cyclophosphamide, *MPAL, mixed phenotype acute leukemia; NHL, non-Hodgkin's lymphoma

Characteristics	early infused group (n=97)	late infused group (n=107)	Р
HVOD	0 (0.0)	1 (1.4)	1.000
CMV antigenemia	22 (22.7)	28 (26.2)	0.626
Bacterial septicemia	16 (16.5)	24 (22.4)	0.297
ES	6 (6.2)	15 (14.0)	0.105
PRCA	1 (1.0)	4 (3.7)	0.372
НС	13 (13.4)	12 (11.2)	0.673

Table S2. Complications post transplantation between the early infused group and late infused group.

HVOD, hepatic veno-occlusive disease, CMV cytomegalovirus, ES engraftment syndrome, PRCA pure red cell aplasia, HC hemorrhagic cystitis

Cause	early infused group	late infused group
Relapse	12 (52.2)	11 (29.7)
Uncontrolled acute GVHD	2 (8.7)	7 (18.9)
Extensive chronic GVHD	1 (4.3)	3 (8.1)
Infection	3 (13.0)	8 (21.6)
MODS	4 (17.4)	6 (16.2)
Others	1 (4.3)	2 (5.4)

Table S3.	Causes	of death	of the ea	arly inf	used gro	oup and	late infused	group.

GVHD graft-versus-host disease, MODS, multi-organ dysfunction syndrome



Key resources table

REAGENT or RESOURCE	SOURCE	IDENTIFIER				
Antibodies						
InVivoMAb anti-mouse	BioXcell	BE0307				
CD16/CD32(2.4G2)		DECCCC				
APC-CY7-anti mouse CD45	BioLegend	103116				
Monoclonal Antibody(30-F11)						
PE-Cy5-anti mouse CD3	eBioscience	15-0032-82				
Monoclonal Antibody (17A2)						
FITC-anti mouse CD4	eBioscience	11-0042-82				
Monoclonal Antibody(RM4-5)						
AF700-anti mouse CD8A	eBioscience	56-0081-82				
Monoclonal Antibody(53-6.7)		70.0444.00				
Super Bright 780 anti-CD44	eBioscience	78-0441-82				
super bright 600 anti mouse	ebioscience	63-0621-82				
CD62L (L-Selectin) Monoclonal						
Antibody (MEL-14)	akiaaaianaa	05 0004 00				
Monoclonal Antibody (00)	edioscience	25-0381-82				
APC anti-mouse H-2Kd	Biolegend	116620				
PE anti mouso H 2Kb	Biologond	116507				
	eBioscience	02-0800-18				
Biological samples						
Detient derived alle UCCT	The First Affiliated Lleavited of the Lleiversity of	N1/A				
Patient-derived allo-HSC I	Science and Technology of China	N/A				
Chamicala pontidae and recomb						
Chemicals, peptides, and recomb						
	BioSnarp	BS143-5g				
RPMI 1640 medium	Gibco	C22400500BT				
Fetal bovine serum	Biological Industries	C04001-500				
RBC Lysing Buffer	BD Pharm Lyse	555899				
BSA	Thermo Fisher Scientific	No. 15260037				
CounteBeads	eBioscience	01-1234-42				
Critical commercial assays						
Cytometric Bead Array (CBA)	BD Biosciences	560485				
mouse cytokine kit						
Experimental models: Organisms/strains						
Mouse: C57BL/6J	GemPharmatech Co., Ltd.	N000013				
Mouse: BALB/c	Shanghai Silaike Experiment Animal Co., Ltd.	N/A				
Software and algorithms						
Flow lo v10 software	Flow lo	https://flowia.hectop				
		dickinson cn				
FCAP Array Software	BD Biosciences	https://legendplex.go				
		gnit.com/workflow				
R software packages	R Foundation for Statistical Computing	https://www.r-				
		project.org				
GraphPad Prism 9.0	GraphPad Software	https://www.graphpa				
		d.com				

1 STAR★METHODS

2 **RESOURCE AVAILABILITY**

3 Lead contact

- 4 Further information and requests for resources and reagents should be directed to and will be
- 5 fulfilled by the lead contact, Cheng Zhan (*<u>zhancheng@ustc.edu.cn</u>*).

6 Materials availability

7 This study did not generate any new unique reagents.

8 Data and code availability

9 The full dataset will be available on the Vivli platform (https://vivli.org/) with publication. This

10 paper does not report any original code. Any additional information required to reanalyze the

11 data reported in this paper is available from the lead contact upon request.

12 EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

13 Patient and transplantation characteristics

All patients received mobilized peripheral blood stem cells as a graft source. The study included 14 169 patients with malignant hematologic diseases and 35 patients with aplastic anemia (AA), 15 with the most frequent diagnosis of hematological malignances being acute leukemia (55.9%). 16 The median age of the whole cohort was 32 (range, 3-62) years, and 109 (53.4%) participants 17 were male. The median infused total nucleated cell (TNC) count was 9.73 (range, 2.35 to 101.32) 18 $\times 10^{8}$ /kg, and the median infused CD34⁺ cell count was 5.12 (range, 0.32 to 67.5) $\times 10^{6}$ /kg. 19 Among all the patients, in addition to cyclosporine (CsA) and mycophenolate mofetil (MMF), 20 21 22 patients received rabbit anti-thymocyte globulin (rATG), 28 patients received post-transplant 22 cyclophosphamide (PT-Cy), 17 patients received both rATG and PT-Cy, and 20 patients received short-term methotrexate (MTX) for GVHD prophylaxis. All surviving patients were 23 24 followed until 31 Dec 2023, and the median follow-up time was 47.5 (range, 7.1 to 106.1) 25 months.

The protocol was approved by the Ethics Committee of the First Affiliated Hospital of the University of Science and Technology of China (USTC) (REC reference: 2024/RE/49). The patients or guardians provided informed consent before transplantation for the use of their data for research, in accordance with the Declaration of Helsinki.

30 **Mice**

31 C57BL/6J (H2k^b) and BALB/c (H2k^d) mice were purchased from GemPharmatech Co., Ltd. 32 (China) and Shanghai Silaike Experiment Animal Co., Ltd., respectively. The animals were 33 maintained in a specific pathogen-free animal facility for at least one week before any further 34 experiments were conducted. All mice were group-housed under a stable environment (22-25°C ambient temperature, humidity 40%-70%) with a 12 h light/12 h dark cycle (lights on from 8 35 36 am to 8 pm) and ad libitum access to water and a standard chow diet (SPF Rodent Feed; 4% 37 fat, 18% protein, 5% crude Fiber; WQJX BIO-Technology, China). All the experiments were performed on adult mice (9-17 weeks old). The care and use of animals in this study were 38 39 approved by the Institutional Animal Use and Care Committee of the University of Science and 40 Technology of China (USTC) (USTCACUC26110122040) and conformed to the institutional guidelines of the USTC, as well as governmental regulations. 41

42 METHOD DETAILS

43 HLA typing, stem cell mobilization and collection

HLA typing of donors and patients was performed using real-time PCR with a high resolution 44 of 10 alleles for HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1. The graft source was 45 unmanipulated mobilized PBSCs in all patients. The donors received four consecutive days of 46 47 granulocyte colony-stimulating factor (G-CSF) (filgrastim) (10 mg/kg/d) for peripheral stem cell mobilization followed by apheresis on day 5. The target stem cell doses for collection and 48 49 infusion for patients were 5×10^8 total nucleated cells (TNCs)/kg (of recipient weight) and 2×10^8 10^6 CD34⁺ cells/kg, respectively. Once the stem cells were collected, they were immediately 50 51 infused into the patient through the central venous catheter.

52 Conditioning regimen and GVHD prophylaxis

53 A total of 156 of 204 (76.5%) patients received myeloablative conditioning (MAC), and 48 54 patients (23.5%) received a reduced-intensity conditioning (RIC) regimen. RIC conditioning 55 regimens were performed in patients who were either older than 40 years or had comorbid severe infection before transplantation. For MAC, 146 patients received a busulfan 56 (Bu)/cyclophosphamide (Cy)-based regimen (Bu, 0.8 mg/kg every 6 hours for 3 or 4 days; Cy, 57 60 mg/kg daily for 2 days) supplemented with fludarabine (Flu) (30 mg/m² daily for 4 days), 58 and 10 patients received a fractionated total body irradiation (TBI) or total marrow irradiation 59 60 (TMI)/Cy regimen (TBI, total 12 Gy, 4 fractions or TMI total 15 Gy, 3 fractions; Cy, 60 mg/kg daily for 2 days), of which 5 patients with cytarabine (Ara-C) added (2 g/m² daily for 4 days). 61 62 For RIC, 35 patients received an irradiation-based conditioning regimen consisting of Flu 30-50 mg/m² for 4-5 days, Cy 14.5-60 mg/kg daily for 2 days and TBI/TMI total 3-4 Gy, 13 patients 63 received a Bu-based conditioning regimen consisting of Flu 30-50 mg/m² for 4-5 days, Cy 60 64 mg/kg daily for 2 days and Bu 0.8 mg/kg every 6 hours for 2 days. 65

66 To prevent GVHD, all patients were given a combination of cyclosporine (CsA) and 67 mycophenolate mofetil (MMF). Twenty-two (10.8%) patients received additional rabbit 68 antithymocyte globulin (rATG), 28 (13.7%) patients received additional post-transplant 69 cyclophosphamide (PT-Cy), 17 (8.3%) patients received both rATG and PT-Cy, and 20 (9.8%) 70 patients were given extra short-term methotrexate (MTX) for GVHD prevention. CsA was 71 started intravenously (2.5-3 mg/kg/day) on day -1 with a target level of 250-300 ng/mL for at 72 least one month before switching to oral intake, and this concentration was tapered by day +60based on the presence of GVHD or disease conditions to maintain the trough concentration at 73 74 100-150 ng/mL and withdrawn by +100 in the absence of GVHD. MMF (25-30 mg/kg/day, p.o. 75 three times per day) was started on day +1 and continued until day +35. rATG (thymoglobulin) 76 was administered from day -6 to -4 at a total dose of 4.5-7.5 mg/kg. PT-Cy was administered 77 on days +3 and +4 at a total dose of 100 mg/kg. MTX was administered intravenously on day +1 at 15 mg/m² and 10 mg/m² on days +3 and +6 post-transplantation. The other supportive 78 treatments adhered to standard protocols based on previously published criteria¹. 79

80 **Definitions**

81 Neutrophil recovery was defined as the first of three consecutive days with a neutrophil count 82 of at least 0.5×10^9 /L, and primary platelet recovery was defined as the first day with a platelet count of at least 50×10^9 /L for seven consecutive days without transfusion support. Primary graft 83 84 failure was defined as failure to achieve an absolute neutrophil count (ANC) of 0.5×10^9 /L with the absence of donor hematopoiesis by 30 days after transplantation. aGVHD and cGVHD were 85 diagnosed and classified using published criteria^{2,3}. Disease recurrence was diagnosed using 86 clinical and pathological standards. Overall survival (OS) was defined as the time from the first 87 88 day of transplantation until death from any cause or the last follow-up date. Disease-free survival (DFS) was defined as the interval between transplantation and disease recurrence, 89 death or the last follow-up date, whichever occurred first. The composite endpoint of GVHD-90 free, relapse-free survival (GRFS) was defined as the first event occurring within 36 months 91 92 after transplantation among Grade III to IV aGVHD, moderate to severe cGVHD, relapse, or 93 death for any reason.

94 Induction of aGVHD in mice

95 Major histocompatibility complex (MHC)-mismatched transplants were performed using 96 BALB/c and C57BL/6J mice as donors and recipients, respectively. Female C57BL/6J mice (9 97 weeks old) received a single fraction of 1100 cGy (137 Cs source) irradiation 5-6 hours prior to 98 transplantation and were intravenously administered 1×10⁷ bone marrow cells plus 6×10⁷ 99 splenocytes from male BALB/c mice (9 weeks old). Starting 2 days before irradiation and 100 continuing until 1 week after transplantation, gentamicin (320 mg/L) was added to the drinking 101 water of the recipients.

102 **Donor cell collection**

For the induction of aGVHD in mice, bone marrow cells were harvested from donor femurs and tibias and resuspended in RPMI 1640 medium (C22400500BT, Gibco) supplemented with 2% fetal bovine serum (FBS) (C04001-500, Biological Industries, Israel). Splenocytes were obtained by gently crushing the spleen through 40 μm mesh filters in RPMI 1640 medium supplemented with 2% FBS to release the cells. Erythrocytes were lysed by incubating the cells in RBC Lysing Buffer (555899, BD Pharm Lyse) for 3 min at room temperature. The

109 preparations were then filtered through a 40 µm strainer to remove debris and washed twice in

110 DPBS. The cells were then counted using a cell counter (Counter star, China) and resuspended

111 in 0.2 mL of DPBS for injection.

112 Flow cytometry

113 To evaluate the activation and differentiation of T cells, the spleen was isolated and processed through a 40-um strainer in RPMI 1640 medium supplemented with 20 mg/ml BSA (Thermo 114 115 Fisher Scientific). After blocking with an anti-mouse CD16/CD32 mAb (1 µg/ml, BE0307, BioXcell) for 10 min at 4°C to prevent nonspecific antibody binding, the cell suspension was 116 co-incubated with APC-Cy7 anti-CD45 (1 µg/ml, 30-F11), PE-Cy5 anti-CD3 (1 µg/ml, 17A2), 117 FITC ant-CD4 (1 µg/ml, RM4-5), AF700 anti-CD8 (1 µg/ml, 53-6.7), Super Bright 780 anti-118 119 CD44 (1 µg/ml, IM7), Super Bright 600 anti-CD62L (L-selectin) (1 µg/ml, MEL-14), PE-Cy7 120 anti-CD38 (1 µg/ml, 90), APC anti-H-2K^d (1 µg/ml, SF1-1.1) and PE anti-H-2Kb (1 µg/ml, AF6-88.5) for 30 min at 4 °C. Fixable viability dye (FVD, eFluor 506, eBioscience) staining 121 was used to exclude dead cells from viable cells. After erythrocytes were lysed with RBC Lysis 122 123 Buffer and washed once in fluorescence-activated cell sorting (FACS) buffer solution, the cells were then passed through a 40 µm cell strainer. The cells were resuspended in 200 µl of FACS 124 125 buffer solution and analyzed by a FACSAria II (BD Biosciences) and FlowJo v10 software (FlowJo, Ashland, OR, USA). A total of 20 µl of microparticles per sample (CounteBeads, 01-126 1234-42, eBioscience) was added to the cell suspensions for absolute counting by flow 127 cytometry. The following equation was used to calculate the absolute cell number 128 (cells / sample): (cell count \times eBeads volume \times eBeads concentration) / eBeads count. 129

For evaluation of peripheral chimerism, blood was first incubated with purified anti-mouse CD16/CD32 mAb for 10 min at 4 °C and then co-incubated with APC anti-H-2K^d (1 μg/ ml) and PE anti-H-2K^b (1 μg/ ml) for 30 min at 4 °C. After staining with fixable viability dye, the cell suspensions were analyzed with a Beckman Coulter Cytoflex (Beckman Coulter, Brea, CA, USA). The obtained data were analyzed using FlowJo v10 software (FlowJo, Ashland, OR, USA). PE-H-2K^b and APC-H-2K^d single staining was performed on blood from naive C57BL/6J and BALB/c mice as positive controls to establish compensatory parameters.

137 Unstained cells were used to establish the analysis area. The percentages of H-2K^{b+} and H-2K^{d+}

138 cell subpopulations were calculated. The donor chimerism was calculated according to the

139 equation: Donor chimerism (%) = $H-2k^{d}$ % / ($H-2K^{b}$ %+ $H-2K^{d}$ %) ×100%.

140 **aGVHD scoring**

Following transplantation, the recipients were monitored for survival once daily and for the occurrence of aGVHD symptomatology twice weekly. The severity of aGVHD was assessed by scoring weight loss, activity, posture (hunching), and fur-ruffling. Each criterion was scored on a scale of 0 to 2, with 0 representing normal, 1 representing mildly abnormal, and 2 representing severely abnormal. The aGVHD clinical scores were calculated by summing the four criteria scores. Mice that were moribund or scored above 5 were euthanized.

147 Measurement of cytokine levels

Blood was drawn from the retrobulbar intraorbital capillary plexus of the recipients and collected in sterile tubes. A Cytometric Bead Array (CBA) mouse cytokine kit (560485, BD Biosciences) was used to measure the serum cytokine levels according to the manufacturer's instructions. FCAP Array Software (v3.0, 652099, BD Biosciences) was used for CBA data analysis.

153 Histology and imaging

154 After an overdose of the anesthetic 2,2,2-tribromoethanol (> 400 mg/kg, i.p.) was injected, the animals were cardiac-perfused with cold phosphate-buffered saline (PBS), followed by 4% 155 paraformaldehyde. The skin, liver, colon, and lungs were harvested and then postfixed in 4% 156 paraformaldehyde overnight with cryoprotection in 30% sucrose. The tissue sections (5 µm) 157 158 were cut with a freezing cryostat (Leica CR 1900) and stained with hematoxylin and eosin. 159 Montage images were acquired and stitched using an automated slider scanner (Exo, Meca Scientific, China). The brightness, contrast, and pseudocolor were adjusted using SlideViewer 160 (Meca Scientific, China). 161

162 Pathologic tissue scoring

163

Histopathological assessments of the skin, liver, colon, and lungs were performed as

previously described^{4,5}. Skin clinical scores were calculated (0 to 10 grades) as the sum of 164 scores for the following criteria: epidermis (0, normal; 1, foci of interface damage in <20% of 165 sections with occasional necrotic keratinocytes; 2, widespread interface damage in >20% of 166 sections); dermis (0, normal; 1, slightly altered with mildly increased collagen density; 2, 167 markedly increased collagen density); inflammation (0, none; 1, focal infiltrates; 2, widespread 168 infiltrates); s.c., fat (0, normal; 1, reduced number of normal adipocytes; 2, serous fat atrophy); 169 and follicles (0, normal number of hair follicles, ~5 per linear millimeter; 1, between 1 and 5 170 171 follicles per linear millimeter; 2, <1 follicle per linear millimeter).

Liver sections were scored (0 to 4 grades) based on bile duct injury (manifest by nuclear hyperchromasia, nuclear crowding, infiltrating lymphocytes, and cytoplasmic vacuolation) and inflammation (infiltration with lymphocytes, neutrophils, and eosinophils) according to the following criteria: the number of involved tracts and the severity of disease in each tract (0, none; 1, few involved tracts with mild involvement; 2, numerous involved tracts but with only mild disease; 3, injury in the majority of tracts; and 4, severe involvement of most tracts).

Colon sections were scored (0 to 4 grades) based on crypt apoptosis (0, rare to none; 1, occasional apoptotic bodies per 10 crypts; 2, few apoptotic bodies per 10 crypts; 3, the majority of crypts contain an apoptotic body; 4, the majority of crypts contain >1 apoptotic body) and inflammation (0, none; 1, mild; 2, moderate; 3, severe, without ulceration; 4, severe, with ulceration).

Lung sections were scored (0 to 4 grades) based on perivascular and peribronchiolar 183 184 cuffing and infiltration for the following criteria: 0, normal; 0.5, minimal perivascular cuffing; 1, perivascular cuffing; 1 to 2 cells in thickness, involving up to 15% of vessels; 1.5, 185 186 perivascular cuffing; 1 to 2 cells in thickness, involving up to 15% of vessels and infiltration into parenchyma proper; 2, perivascular cuffing; 2 to 3 cells in thickness, involving up to 25% 187 of vessels and infiltration into parenchyma proper; 2.5, perivascular cuffing; 2 to 3 cells in 188 thickness, involving 25% to 50% of vessels and infiltration into parenchyma proper; 3, 189 190 perivascular cuffing; 4 to 5 cells in thickness, involving 25% to 50% of vessels, peribronchiolar 191 cuffing (2 to 3 cells) and infiltration into parenchyma proper; 3.5, perivascular cuffing; 6 to 7

192 cells in thickness, involving greater than 50% of vessels, peribronchiolar cuffing (4 to 5 cells);

and 4, perivascular cuffing, greater than 8 cells in thickness, involving greater than 50% of

194 vessels, peribronchiolar cuffing (>6 cells).

195 QUANTIFICATION AND STATISTICAL ANALYSIS

196 Statistical analysis of clinical data

The quantitative variables are represented by the median and range. The qualitative factors are 197 198 expressed as frequencies and proportions. Quantitative variables were calculated and compared using Student's t test or the Mann–Whitney U test. Qualitative variables were analyzed using 199 the chi-square test or Fisher's exact test. Ordinal data were analyzed using the Cochran-200 Armitage trend test. To calculate the cumulative incidence of engraftment, aGVHD, cGVHD, 201 202 transplant-related mortality (TRM), and relapse, cumulative incidence curves were constructed in a competing risk setting, with death considered a competing event, and the results were 203 compared using Gray's test ¹⁵. TRM and relapse were regarded as competing risk factors. The 204 Kaplan-Meier method and log-rank test were used to compare the probabilities of 3-year 205 206 overall survival (OS), disease-free survival (DFS), and GVHD free, relapse-free survival (GRFS). 207

To determine the risk factors for Grade II-IV and Grade III-IV aGVHD, we conducted univariate and multivariate analyses with a Fine-Gray proportional hazards regression model¹⁶. In the regression model, we included the timing of stem cell infusion as an ordinal variable in the univariate and multivariate analyses. All variables with a 2-sided *P* value less than 0.2 were included in the multivariate analysis. The R software package, version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria), was used for statistical analyses. A 2-sided *P* value less than 0.05 was considered to indicate statistical significance.

215 Statistical analysis of the mouse experiments

Statistical analysis was performed using GraphPad Prism 9.0 (GraphPad Software, CA, USA).
Statistical differences in the data were determined using an unpaired Student's *t* test for twogroup comparisons, two-way analysis of variance (ANOVA) followed by the Bonferroni post

219 hoc test for multiple comparisons, and the log-rank test for survival (Kaplan-Meier survival

220 curves) difference comparisons, as indicated in all the figure legends. The data are shown as

the means \pm SEMs.

222

223 **References**

Sun G, Tang B, Song K, et al. Unrelated cord blood transplantation vs. HLA-matched sibling
 transplantation for adults with B-cell acute lymphoblastic leukemia in complete remission: superior
 OS for patients with long-term survival. Stem Cell Res Ther 2022;13(1):500. DOI: 10.1186/s13287 022-03186-3.

228 Harris AC, Young R, Devine S, et al. International, Multicenter Standardization of Acute Graft-2. 229 versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD 230 International Consortium. Biology of Blood and Marrow Transplantation : Journal of the American 231 Society For Blood Transplantation and Marrow 2016;22(1)(In eng). DOI: 232 10.1016/j.bbmt.2015.09.001.

Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development
 Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis
 and Staging Working Group report. Biol Blood Marrow Transplant 2015;21(3):389-401 e1. DOI:
 10.1016/j.bbmt.2014.12.001.

Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target antigens
 determine graft-versus-host disease phenotype. J Immunol 2004;173(9):5467-75. (In eng). DOI:
 10.4049/jimmunol.173.9.5467.

5. Blazar BR, Taylor PA, McElmurry R, et al. Engraftment of severe combined immune deficient
mice receiving allogeneic bone marrow via In utero or postnatal transfer. Blood 1998;92(10):394959. (In eng).

243